Despite recent market turbulence, Oppenheimer Asset Management expressed continued optimism about equities in a statement ...

As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Biomea Fusion (BMEA – Research Report), with a price ...

Oppenheimer said on Wednesday it no longer expects growth in U.S. investment banking revenue this year and slashed its ...

Joshua Oppenheimer made his name directing two disturbing documentaries, The Act of Killing (2012) and The Look of Silence ...

Oppenheimer called the expected M&A rebound under the Trump administration “delayed or cancelled” and downgraded to "perform" ...

Yet, MAD still dominates countries’ nuclear thinking. Opinion: Our nuclear weapons are much more powerful than Oppenheimer's atomic bomb At a time of profound global changes and instability ...

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...

A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...

Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had one of the most incredibly stacked casts in recent memory. Jack Quaid ...